Anyone discouraged by the continued absence of a prostate cancer screening programme, the difficulties in getting a clear ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting cancerous ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...